Leerink Swann Comments on Sarepta Therapeutics Inc’s FY2019 Earnings (SRPT)

Sarepta Therapeutics Inc (NASDAQ:SRPT) – Analysts at Leerink Swann issued their FY2019 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will earn $0.11 per share for the year. Leerink Swann has a “Outperform” rating and a $47.00 price objective on the stock.

A number of other research analysts also recently commented on the stock. Vetr raised shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating and set a $34.53 price objective for the company in a research report on Tuesday, March 14th. SunTrust Banks, Inc. raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the company from $30.00 to $30.97 in a research report on Wednesday, April 5th. Cowen and Company reissued an “outperform” rating and issued a $62.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, March 11th. Robert W. Baird reissued a “buy” rating and issued a $102.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, January 10th. Finally, Nomura started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, March 1st. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $56.74.

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

ILLEGAL ACTIVITY WARNING: “Leerink Swann Comments on Sarepta Therapeutics Inc’s FY2019 Earnings (SRPT)” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.wkrb13.com/markets/2065222/leerink-swann-comments-on-sarepta-therapeutics-incs-fy2019-earnings-srpt.html.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 2.498% during trading on Thursday, hitting $32.625. 1,374,330 shares of the stock traded hands. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73. The company’s 50 day moving average is $30.56 and its 200 day moving average is $35.08. The company’s market capitalization is $1.79 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.62. The company had revenue of $5.42 million for the quarter, compared to analysts’ expectations of $4.86 million. During the same quarter in the prior year, the firm earned ($1.44) earnings per share. The company’s revenue was up 333.6% on a year-over-year basis.

Several institutional investors have recently modified their holdings of the stock. Emerald Advisers Inc. PA boosted its position in shares of Sarepta Therapeutics by 5.4% in the third quarter. Emerald Advisers Inc. PA now owns 248,327 shares of the biotechnology company’s stock valued at $15,250,000 after buying an additional 12,821 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $16,154,000. BlackRock Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 20.3% in the third quarter. BlackRock Investment Management LLC now owns 201,813 shares of the biotechnology company’s stock valued at $12,393,000 after buying an additional 34,025 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Sarepta Therapeutics by 2.0% in the third quarter. Rhumbline Advisers now owns 47,674 shares of the biotechnology company’s stock valued at $2,928,000 after buying an additional 955 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Sarepta Therapeutics by 5.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,107,119 shares of the biotechnology company’s stock valued at $67,988,000 after buying an additional 58,501 shares during the last quarter. Institutional investors own 76.75% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

5 Day Chart for NASDAQ:SRPT

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065222/leerink-swann-comments-on-sarepta-therapeutics-incs-fy2019-earnings-srpt.html

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.